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Abstract
Introduction: Our group has previously employed array Comparative Genomic Hybridization (aCGH) to assess the
genomic patterns of BRCA1-mutated breast cancers. We have shown that the so-called BRCA1-like
aCGH profile is
also present in about half of all triple-negative sporadic breast cancers and is predictive for benefit from intensified
alkylating chemotherapy. As aCGH is a rather complex method, we translated the BRCA1
aCGH profile to a Multiplex
Ligation-dependent Probe Amplification (MLPA) assay, to identify both BRCA1-mutated breast cancers and sporadic
cases with a BRCA1-like
aCGH profile.
Methods: The most important genomic regions of the original aCGH based classifier (3q22-27, 5q12-14, 6p23-22,
12p13, 12q21-23, 13q31-34) were mapped to a set of 34 MLPA probes. The training set consisted of 39 BRCA1-
like
aCGH breast cancers and 45 non-BRCA1-like
aCGH breast cancers, which had previously been analyzed by aCGH.
The BRCA1-like
aCGH group consisted of germline BRCA1-mutated cases and sporadic tumours with low BRCA1 gene
expression and/or BRCA1 promoter methylation. We trained a shrunken centroids classifier on the training set and
validation was performed on an independent test set of 40 BRCA1-like
aCGH breast cancers and 32 non-BRCA1-
like
aCGH breast cancer tumours. In addition, we validated the set prospectively on 69 new triple-negative tumours.
Results: BRCAness in the training set of 84 tumours could accurately be predicted by prediction analysis of
microarrays (PAM) (accuracy 94%). Application of this classifier on the independent validation set correctly
predicted BRCA-like status of 62 out of 72 breast tumours (86%). Sensitivity and specificity were 85% and 87%,
respectively. When the MLPA-test was subsequently applied to 46 breast tumour samples from a randomized
clinical trial, the same survival benefit for BRCA1-like tumours associated with intensified alkylating chemotherapy
was shown as was previously reported using the aCGH assay.
Conclusions: Since the MLPA assay can identify BRCA1-deficient breast cancer patients, this method could be
applied both for clinical genetic testing and as a predictor of treatment benefit. BRCA1-like tumours are highly
sensitive to chemotherapy with DNA damaging agents, and most likely to poly ADP ribose polymerase (PARP)-
inhibitors. The MLPA assay is rapid and robust, can easily be multiplexed, and works well with DNA derived from
paraffin-embedded tissues.
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Breast cancers are genomically highly instable, and array
Comparative Genomic Hybridization (aCGH) analysis
shows numerous gains and losses of whole chromo-
somes or parts of chromosomes. Previous studies have
shown that hereditary breast cancer tends to develop
specific genomic alterations, based on which they can be
distinguished from sporadic tumours [1-5]. Our group
has employed aCGH to assess the genomic patterns of
BRCA1-mutated breast cancers [6]. This has resulted in
a BRCA1-like classifier based on specific aberrations of
BRCA1-mutated breast cancers compared to sporadic
tumours. This classifier allows identification of familial
breast cancer cases in patients whose germ line BRCA1-
mutation status is unknown [6] or assists in the classifi-
cation of BRCA1 variants of unknown significance [6,7].
It is currently employed in routine diagnostics in our
clinical genetic centre. The BRCA1-like aCGH pattern
may also be present in sporadic breast cancers, which
frequently show evidence of impaired BRCA1 function
due to other causes than mutation, for example, methy-
lation [8-10]. In fact, we and others have shown that
sporadic basal-like breast cancers resemble BRCA1
mutated cancers in many different ways [11-13]. This
concept of “BRCAness” in sporadic cancers is under
s t u d yi nm a n yc e n t r e sa si tm a yh a v ei m p l i c a t i o n sf o r
treatment selection [14-16].
BRCA1 mutated cancers are more sensitive to DNA
damage inducing chemotherapy than their sporadic
counterparts [17]. This can be explained by their defec-
tive homologous recombination pathway, a DNA repair
mechanism in which BRCA-proteins have a major role.
In BRCA1-associated cancers, the homologous recombi-
nation defect renders tumours highly sensitive to che-
motherapy that causes double strand breaks (DSBs) in
the DNA replication phase of the cell cycle, when
homologous recombination is the dominant DSB repair
mechanism. This observation also explains the sensitiv-
ity of tumours in BRCA1 mutation carriers to the novel
class of poly ADP ribose polymerase (PARP) inhibitors
[15].
We have shown in two independent studies that
approximately half of all triple-negative (TN) tumours
have a BRCA1-like aCGH profile [9,10]. We have
hypothesized that these tumours harbour a homologous
recombination deficiency and thus would be very sensi-
tive to DSB-inducing chemotherapy, similar to tumours
arising in BRCA1-mutation carriers. In agreement with
this assumption, we have demonstrated in a retrospec-
tive analysis of a randomized controlled trial that the
so-called BRCA1-like
aCGH profile was strongly predictive
for benefit from intensive carboplatin-based alkylating
chemotherapy [10].
As the aCGH assay is a rather complex method,
requiring a reasonable amount of high quality DNA and
specialized equipment, we endeavoured to devise an
alternative method to determine the BRCA1-like profile
in breast cancers suitable for routine use in pathology
laboratories. Moreover, a commercially available test
would make it possible to implement this approach uni-
formly in pathology laboratories across various institutes
and countries. To achieve this, we translated the
BRCA1
aCGH profile to a Multiplex Ligation-dependent
Probe Amplification (MLPA) assay. MLPA is a method
based on amplification and relative quantification of the
ligated adjacent probes, which can target up to 50 differ-
ent genomic regions that show diagnostically or clini-
cally significant copy number changes in patient
samples [18]. It is a simple and robust assay, which can
be highly multiplexed and requires only a small amount
of input DNA that can easily be obtained from paraffin-
embedded tumour material. These characteristics make
MLPA an ideal method for a clinical application.
In this study, we test the performance of a MLPA-kit,
by a direct comparison with aCGH BRCA1 classifiers
scores. In addition, we show how this kit can be used to
identify both BRCA1-mutated breast cancers and spora-
dic cases with a BRCA1-like
aCGH profile and we present
evidence that the kit can be used for treatment
selection.
Materials and methods
Patient selection
Four series of breast cancer specimens were employed:
(i) 52 tumours from the NKI-clinical genetic centre,
from which the BRCA1 mutational status was known.
These patient samples had also been used to build the
original aCGH BRCA1-like classifier [6]; (ii) 58 tumour
samples from a neoadjuvant chemotherapy trial at the
NKI-AVL [9]; (iii) 46 triple-negative tumour samples
from a randomized study in The Netherlands that com-
pared intensified alkylating chemotherapy with conven-
tional dose chemotherapy [19]; and (iv) 69 triple-
negative tumours, collected at the Deventer Hospital.
All either participated in clinical studies, which had
been approved by the institutional review board, or
received chemotherapy according to the standard arm of
one of these studies off protocol. The local medical
ethics committee approved the study protocols. At the
time of building the classifier, DNA from 84 samples
from the first two sets was available, so these samples
were used as the training set. To test the classifier in
new samples, we collected 26 additional cases from the
first two series and used all 46 samples from the rando-
mized controlled trial. In addition, when the classifier
was ready for prospective validation, we applied the
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samples. All tumours had previously been studied by
aCGH, and thus BRCA1-like profile scores were avail-
able. See Table 1 for an overview of all samples used.
DNA isolation
DNA from all tumours was available from previous stu-
dies [6,9,10]. Briefly, DNA from the clinical genetics ser-
ies, the randomized trial series, and the Deventer series
was isolated from formalin-fixed, paraffin-embedded
(FFPE)-tumour tissue, using NaSCN and purified with a
DNeasy column (Qiagen DNA extraction kit, Qiagen,
Venlo, The Netherlands). DNA from the neoadjuvant
chemotherapy study samples was isolated from fresh-
frozen tumour tissue, using RNAzol (Tel-test) and Back
Extraction Buffer (consisting of guanidine thiocyanate,
sodium citrate, and Tris). As reference DNA, we used
commercially available human Promega female DNA
( P r o m e g a ,M a d i s o n ,W I ,U S A ) .D N As a m p l e sf r o ma l l
three breast cancer groups had previously been typed
with a 3.5 k BAC array and results have been published
before [6,9,10]. We used the original BRCA1-like classi-
fier developed by Simon Joosse [6,9,10], which was
adapted by Vollebergh et al. [10].
MLPA
Multiplex Ligation-Dependent Probe Amplification
(MLPA) is a high throughput, PCR based method to
determine the relative copy number of various DNA tar-
get sequences in a small quantity of human DNA. It is
based on the annealing of a mixture of oligonucleotides
on their cognate DNA sequences. Each MLPA probe
consists of two parts, and the longer part of the probe
contains a stuffer DNA sequence of variable length (19
to 370 bp), which allows multiplex detection of amplifi-
cation products (120 nt to 500 nt) using a capillary
sequencer. The amount of amplification product is pro-
portional to the number of target sequences and thus
the number of target recognition sites can be quantified.
The standard MLPA-protocol, which was used here, has
been described elsewhere [18]. In short, 100 ng target
DNA/5 μlo f1 0m MT r i s( p H8 ) ,0 . 1m Me t h y l e n e d i a -
minetetraacetic acid was denaturated for five minutes at
98°C after which 3 μl of the probemix mixture was
added. The sample DNA and P376-B1 MLPA probemix
mixture was heated at 95°C for 1 minute and incubated
at 60°C overnight (16 h). Ligation was performed with
the temperature-stable Ligase-65 enzyme (MRC-Hol-
land, Amsterdam, The Netherlands) for 15 minutes at
54°C. Then the ligase was inactivated by incubation for
five minutes at 98°C. Ten microliters of this ligation mix
were premixed with 30 μl PCR buffer and transferred
into a PCR machine at 60°C. Subsequently, a 10 μlm i x
was added containing deoxynucleoside triphosphate,
Taq polymerase and one unlabeled and one carboxy-
fluorescein-labeled (FAM) PCR primer, which are com-
plementary to the universal primer sequences present in
all MLPA probes. PCR was carried out for 35 cycles (30
sec at 95°C, 30 sec at 60°C and 60 sec at 72°C). The
fragments were analyzed on an ABI model 310 or 3700
capillary sequencer (Applied Biosystems, Nieuwerkerk
aan den Ijssel, The Netherlands) using Genescan-ROX
500 size standards. Fragment analysis was performed
using Genescan and Genotyper software (Applied
Biosystems).
MLPA data normalization
To automate the interpretation of the fragment analysis,
the relative quantity of the amplified probes in each
sample was determined using a template in Excel
(Microsoft, Redmond, WA, USA) [20]. For this purpose,
the relative peak areas for each probe were calculated as
fractions of the total sum of peak areas in each sample.
Subsequently, the fraction of each peak was divided by
the average peak fractions of the corresponding probe in
control samples (Promega female reference DNA).
Class prediction
Data values from Excel for all the 34 target specific
probes were used for prediction analysis for microarrays
(PAM). In brief, the nearest shrunken centroids method
[21] was applied to the training set of 84 tumours with
Table 1 Sample characteristics
Training
set
Test set Extra
Validation
set
n (%) n (%) n (%)
Total 84 100% 72 100% 69 100%
Patient series
Clinical genetics centre 34 40% 18 25%
Neoadjuvant series 50 60% 8 11%
Randomised controlled trial series 0 0% 46 64%
Subtype
HER2+ 11 13% 5 7% 0 0%
ER+HER2- 22 26% 10 14% 0 0%
Triple-negative (TN) 52 61% 57 79% 69 100%
ER expression
Negative 57 67% 59 82% 69 100%
Positive 28 33% 13 18% 0 0%
BRCA1 mutation
BRCA1 mutation 16 19% 17 24% 7 10%
No mutation 19 23% 44 61% 0 0%
Unknown 49 58% 11 15% 62 90%
BRCA1like status aCGH
BRCA1-like 37 44% 40 56% 50 72%
Sporadic-like 47 56% 32 44% 19 28%
aCGH, array Comparative Genomic Hybridisation.
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classification performance was evaluated by a 10-times-
repeated 10-fold cross validation as described previously.
Subsequently, the obtained classifier was tested on the
72-sample test set. The BAC aCGH BRCA1-classifier [6]
(adapted by Vollebergh et al. [10]) was considered as
the gold standard. For the MLPA classifier the cut-off
value to classify a sample as ‘BRCA1-like’ was set at 0.5.
Below this score, a sample was classified as ‘Sporadic-
like’.
Results
Translation of the aCGH BRCA1-like classifier to a MLPA
kit
Different classifiers were developed over time, one con-
sisting of 371 probes [6], and one containing 191 probes
[6]. The top centroids were selected from the 191 classi-
fier and genomic location of the BACs was listed (most
centroids were in chromosome 3q22-27 (gain), 5q12-14
(loss), 6p23-22 (gain), 12p13 (gain), 12q21-23 (loss), and
13q31-34 (gain)) [6]. In addition, we added probes for
3p21 (loss), 10p13-15 (gain), 10q23 (loss) (PTEN
region), 14q22-24 (loss), 15q15-21 (loss), as these
regions also made an important contribution to the
BAC-classifier. In those regions we searched for existing
MLPA probes from the MRC-Holland MLPA probe
database. We attempted to cover each genomic region
with at least two, preferably three, MLPA probes, as the
BAC clones were also quite large, and the BAC classifier
covered, in general, large genomic regions. When no
probes were available for a specific region, new probes
were designed. This process resulted in several versions
of the MLPA BRCA1-like kit. The kits were tested to
evaluate the performance of the probes, also in DNA
from normal tissue and in DNA from FFPE-derived tis-
sues. The final version of the kit (fourth) gave the best
performance and was used for further validation. Pre-
vious versions either did not cover every region by a
minimum of two probes, contained probes not working
in FFPE derived DNA, or contained probes which failed
for another reason. The final version of the kit con-
tained 34 target specific probes, corresponding to the
BAC classifier regions, 7 reference probes, randomly
spread over the genome and in regions not affected in
breast cancer, 2 probes for BRCA1 and 2 probes for
BRCA2, resulting in a total of 45 probes (Table 2). The
correlation between a BAC probe and its corresponding
MLPA probe ranged between 0.79 and 0.96. The aver-
age correlation between two or three MLPA probes
spanning the same genomic area was 0.94.
BRCA1-like MLPA predictor
To build the BRCA1-like MLPA classifier we used a set
of samples from BRCA1 mutation carriers and a set of
sporadic tumours classified as BRCA1-like by the aCGH
classifier. These ‘positive’ samples were compared with
breast tumours that were known to have a sporadic-like
profile by aCGH. Using this approach, we trained the
Table 2 All probes of the BRCA1-like MLPA kit
Probe name Genomic location Stuffer length Probe type
SEMA3B - 3 03-050282676 140 Test_loss
RASSF1 - 1 03-050353347 328 Test_loss
DEPDC1B - 2 05-060018734 241 Test_loss
MCCC2 - 16 05-070984253 409 Test_loss
GPR98 - 90 05-090495354 184 Test_loss
APC - 1 05-112071337 226 Test_loss
LMNB1 - 7 05-126184598 214 Test_loss
PTEN - 1 10-089614110 233 Test_loss
PTEN - 9 10-089714978 463 Test_loss
CEP290 - 26 12-087019051 400 Test_loss
BTG1 AREA - 29 12-090905485 155 Test_loss
PAH - 3 12-101812669 202 Test_loss
BMP4 - 4 14-053488631 454 Test_loss
GCH1 - 6b 14-054380537 283 Test_loss
RDH12 - 7 14-067263397 319 Test_loss
THBS1 - 1 15-037660496 346 Test_loss
CAPN3 - 16 15-040479002 148 Test_loss
FBN1 - 4 15-046679657 172 Test_loss
CASR - 7 03-123485226 483 Test_gain
ATR - 47 03-143651063 373 Test_gain
HLTF - 1 03-150286916 193 Test_gain
PDCD10 - 5 03-168905298 382 Test_gain
PIK3CA - 2 03-180399607 427 Test_gain
TPMT - 5 06-018247829 265 Test_gain
HFE - 2 06-026198995 301 Test_gain
FANCE - 7 06-035535433 274 Test_gain
GATA3 - 1 10-008136773 136 Test_gain
CUGBP2 - 6 10-011017023 364 Test_gain
FGF23 - 1 12-004358933 436 Test_gain
ETV6 - 5 12-011913651 474 Test_gain
ABCC4 - 23 13-094525703 247 Test_gain
PCCA - 6 13-099607548 418 Test_gain
PCCA - 11 13-099718959 291 Test_gain
FGF14 - 2 13-101366785 492 Test_gain
BRCA1 - 20 17-038462662 390 BRCA probe
BRCA1 - 2 17-038529544 167 BRCA probe
BRCA2 - 5 13-031798006 337 BRCA probe
BRCA2 - 11 13-031812003 130 BRCA probe
REFERENCE 02-071430713 355 Reference
REFERENCE 02-267097 310 Reference
REFERENCE 07-075448405 124 Reference
REFERENCE 07-116126400 160 Reference
REFERENCE 10-042932039 178 Reference
REFERENCE 10-075547782 220 Reference
REFERENCE 14-019994693 208 Reference
MLPA, Multiplex Ligation-dependent Probe Amplification
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sporadic cases with a BRCA1-like profile. The aCGH
BRCA1-score was considered as the gold standard and
it was used for class labelling. The resulting training set
consisted of 84 breast tumours: 39 BRCA1-like
aCGH and
45 Sporadic-like
aCGH tumours. We used Shrunken Cen-
troids from the package PAM to discriminate between
BRCA1-like and Sporadic-like tumours. A 10-fold cross-
validation resulted in an optimal delta of 0, and this
parameter setting resulted in the smallest number of
misclassifications. As a consequence, all 34 test probes
were used for further classification. The overall error
rate in the training set was 6% (Table 3). See Table 4
for the top 10 centroids contributing to the MLPA
classifier.
Results test set prediction
The classifier trained on the training set was tested in a
new group of 72 tumours. This test set consisted of (i)
18 tumours from the clinical genetics centre; (ii) 8
tumours from the neoadjuvant series; and (iii) 46 triple-
negative tumour samples from a randomized controlled
clinical trial that studied the efficacy of intensified alky-
lating chemotherapy in breast cancer. Inclusion of this
last series in the test set enabled us to assess whether
the MLPA classifier had the same value in chemother-
apy benefit selection as the original aCGH assay (10). Of
the 72 test set tumours, 62 samples were correctly clas-
sified and 10 were misclassified when the aCGH test
was regarded as the gold standard, resulting in an over-
all error rate of 14% (Table 5). The sensitivity was 85%
and the specificity was 87%.
Prospective validation
We wanted to validate the classifier in an independent
set of triple-negative samples, which can be viewed as a
prospective validation. For this purpose, we used 69 tri-
ple-negative tumours from the Deventer Hospital, which
had recently been typed by aCGH (manuscript in pre-
paration). A total of 64 out of 69 tumours were
correctly classified, resulting in an accuracy of 93% and
an error rate of 7%. Three BRCA1-like
aCGH tumours
were classified as Sporadic-like by MLPA and two
Sporadic-like
aCGH tumours were typed as BRCA1-like.
Performance of the classifier to detect BRCA1-mutation
carriers and BRCA1 promoter methylation
By combining training, test set and the prospective vali-
dation set, we had 40 tumours from patients known to
be BRCA1 mutation carriers. Five of these 40 tumours
did not show a BRCA1-like pattern on MLPA and, simi-
larly, five of the 40 were not BRCA1-like according to
aCGH (Table 6). Two of the discordant tumours tested
Sporadic-like in both the MLPA and the aCGH assay,
whereas six of the BRCA1-mutation carriers were either
classified Sporadic-like by MLPA or aCGH. Interest-
ingly, one tumour which was classified as Sporadic-like
by both MLPA and aCGH was hormone receptor
Table 3 Results from the 10-fold cross-validation on the
training set
Predicted with MLPA
BRCA1-like Sporadic-like Total
aCGH result
BRCA1-like 36 3 39
Sporadic-like 2 43 45
Total 38 46 84
Number Percentage
Error 5/84 6%
Accuracy 79/84 94%
aCGH, array Comparative Genomic Hybridisation; MLPA, Multiplex Ligation-
dependent Probe Amplification
Table 4 Top centroids from the BRCA1 MLPA classifier
Rank Probe
name
Genomic
position
BRCA1-like
score
Sporadic
score
1 MCCC2 -
16
05-070984253 -0.4351 0.3771
2 PAH - 3 12-101812669 -0.2951 0.2558
3 CAPN3 - 16 15-040479002 -0.2929 0.2538
4 BMP4 - 4 14-053488631 -0.2814 0.2439
5 PIK3CA - 2 03-180399607 0.2768 -0.2399
6 GCH1 - 6b 14-054380537 -0.2763 0.2394
7 DEPDC1B -
2
05-060018734 -0.265 0.2297
8 GATA3 - 1 10-008136773 0.2488 -0.2156
9 FBN1 - 4 15-046679657 -0.2485 0.2153
10 GPR98 - 90 05-090495354 -0.2458 0.213
MLPA, Multiplex Ligation-dependent Probe Amplification.
Table 5 Classification results of the test set
Predicted with MLPA
BRCA1-like Sporadic-like Total
aCGH result
BRCA1-like 35 6 41
Sporadic-like 4 27 31
Total 39 33 72
Number Percentage
Sensitivity 35/41 85%
Specificity 27/31 87%
PPV 35/39 90%
NPV 27/33 82%
Error 10/72 14%
Accuracy 62/72 86%
aCGH, array Comparative Genomic Hybridisation; MLPA, Multiplex Ligation-
dependent Probe Amplification; NPV, negative predictive value; PPV, positive
predictive value
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were triple-negative.
For a subset of samples we had methylation and real-
time PCR data for BRCA1. We assumed that tumours
w i t haB R C A 1 - l i k ep r o f i l ec o u l dh a v eB R C A 1p a t h w a y
inactivation due to other causes than a mutation.
Twenty tumours showed BRCA1 promoter methylation.
A total of 18 (90%) of these were BRCA1-like by MLPA,
and 19 (95%) by aCGH (Table 6). Thirteen tumours
showed low BRCA1 gene expression measured by qRT-
PCR. These tumours all had a BRCA1-like pattern by
MLPA, and all but one by aCGH.
Ability of the MLPA-set to predict chemotherapy benefit
In a previous publication, we reported a significantly
better survival in patients with a BRCA1-like
aCGH
tumours treated with an intensified alkylating regimen
compared to conventional dose chemotherapy [10]. To
study the performance of the MLPA assay, all TN
tumours from this randomized controlled trial from
which a sufficient amount of DNA was available were
included in the test set, resulting in a total of 46
tumours. Only triple-negative tumours were included, as
almost all BRCA1-like
aCGH tumours are triple-negative.
We compared this subset of 46 tumours for baseline
clinicopathological variables, like T-stage, N-stage and
grade, with all 149 TN samples of the randomized con-
trolled trial. No difference in either variable was seen
(data not shown).
Recurrence-free survival by MLPA analysis was ana-
lyzed, in the same way as previously reported for aCGH
analysis (Figure 1) [10]. The same pattern was observed
for the aCGH as for the MLPA classifier. The tumours
with a Sporadic-like profile do not show a significant
difference between conventional and intensive che-
motherapy (Figure 1A, C). However, the BRCA1-like
tumours show a significantly better recurrence-free sur-
vival after intensive chemotherapy than after conven-
tional dose chemotherapy (Figure 1B, D) (P = 0.002 for
aCGH and P = 0.024 for MLPA). Although not all tri-
ple-negative aCGH samples from the original publica-
tion [10] could be analyzed with MLPA due to limited
material, the difference in re c u r r e n c ef r e es u r v i v a l
between BRCA1-like and Sporadic-like samples depend-
ing on whether or not intensive chemotherapy is given,
remained (Figure 1).
Discussion
In this study, we describe the design, testing and valida-
tion of a Multiplex Ligation-Dependent Probe Amplifi-
cation (MLPA) kit to determine BRCA1-like genomic
profiles. Our findings suggest that this classifier can be
used both in clinical genetic testing and in treatment
response prediction. In the clinical genetic setting, the
classifier could be used in addition to conventional
BRCA1 mutation testing: as a tool to classify BRCA1
variants of unknown significance or to identify potential
BRCA1 mutations other than the mutations that are
currently screened for. MLPA is a rapid, cost-efficient
method, suitable for FFPE tissue derived DNA, and,
therefore, potentially useful for routine clinical
application.
In previous work, we developed an aCGH-based clas-
sifier recognizing the genomic pattern of BRCA1-
mutated breast tumours. We showed that this classifier
could identify hereditary breast tumours, for which no
mutation was identified by routine clinical screening [6].
In addition, we showed that this BRCA1-like pattern
was also observed in sporadic breast cancer patients,
and was predictive for treatment benefit [10]. Currently,
several prognostic tests for breast cancer are being eval-
uated in clinical studies or have already been FDA
approved [22,23]. However, predictive tests seem to be
more difficult to develop. Even more than for other
breast cancer subtypes, there is an urgent need for tar-
geted therapies for triple-negative tumours, as the only
systemic treatment option for this tumour group con-
tinues to be chemotherapy. With the clinical introduc-
tion of the PARP inhibitors, hope has been raised that
at least the triple-negative tumours defective in homolo-
gous recombination could benefit from this treatment
[14,24]. Our MLPA test can recognize both BRCA1-
mutated and sporadic tumours with a BRCA1-like geno-
mic profile. We hypothesized that those tumours show
BRCAness [13] and thus would be highly sensitive to
this new class of targeted drugs. When we applied the
MLPA assay to tumours of patients treated in a rando-
mized controlled trial, we ob s e r v e dt h a tp a t i e n t sw i t ha
BRCA1-like MLPA profile had a significantly better
recurrence-free survival after intensified alkylating che-
motherapy than patients with a Sporadic-like profile.
Although the groups were small, this lends further sup-
port to the predictive power of our new MLPA
Table 6 BRCA1-like profile is samples with a BRCA1-
mutation, -methylation or low gene expression
BRCA1 classification n (%)
BRCA1 mutated by sequencing 40
BRCA1-like by MLPA 35 (88%)
BRCA1-like by aCGH 35 (88%)
BRCA1 promoter methylation 20
BRCA1-like by MLPA 18 (90%)
BRCA1-like by aCGH 19 (95%)
BRCA1 low gene expression 13
BRCA1-like by MLPA 13 (100%)
BRCA1-like by aCGH 12 (92%)
aCGH, array Comparative Genomic Hybridisation; MLPA, Multiplex Ligation-
dependent Probe Amplification
Lips et al. Breast Cancer Research 2011, 13:R107
http://breast-cancer-research.com/content/13/5/R107
Page 6 of 9BRCAness test, which appears to be as accurate as the
original aCGH test.
The clinical application of a DNA test is associated
with more requirements for practicability than an assay
used for research purposes only. It must be rapid as the
patient and the physician are in need of a result within
days; it should be feasible using standard equipment;
and it must be cost effective. In addition, it is an advan-
tage if the test can be performed on FFPE tissue, as this
is the material routinely available in clinical pathology
laboratories. MLPA fulfils all these criteria. Therefore,
we believe that this assay makes BRCAness testing a
viable option for triple-negative tumours. The kit is now
ready for prospective clinical validation and it can
already be used along with aCGH in the clinical genetics
testing mentioned previously.
Currently, there is no gold standard for BRCAness. In
this study we used MLPA as a surrogate, in the pre-
vious, aCGH. Others have used gene expression [25],
methylation [16] and RAD51 [26]. However, none of
those methods is perfect and generally accepted for
BRCAness determination, and in not all studies data
A        B  
C        D  
Figure 1 Survival analysis. Association of BRCA1-like classification with array Comparative Genomic Hybridisation (aCGH) and with Multiplex
Ligation-dependent Probe Amplification (MLPA), with outcome after intensive alkylating chemotherapy and conventional dose chemotherapy.
Kaplan-Meier survival curves according to the BRCA1 classification of tumours. The patients had been randomly assigned to either intensified
dose chemotherapy or conventional dose chemotherapy. (a) Recurrence-free survival (RFS) of Sporadic-like CGH triple-negative (TN) patients (log
rank test: P = 0.543), (b) RFS of BRCA1-likeCGH TN patients (P = 0.002), (c) RFS of Sporadic-like MLPA TN patients (P = 0.625), (d) RFS of BRCA1-
like MLPA TN patients (P = 0.024).
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riers. We have shown a high degree of concordance
with the aCGH-based BRCA1-like classifier (94% in the
training set and 86% in the test set). The concordance
was, however, not perfect. In fact, the BRCA1-aCGH is
not perfect as well as in the original publication two
BRCA1-mutation carriers were not classified as BRCA1-
like tumours [6]. Also, in subsequent series, some BRCA1
mutated cases were missed [10] and were not identified as
BRCA1-like
aCGH. When we compared misclassifications
between the BRCA1 aCGH and MLPA classifiers we
found that five BRCA1-mutated tumours were not classi-
fied as BRCA1-like with MLPA and five were missed by
aCGH (not completely overlapping). Based on these num-
bers we can conclude that MLPA and aCGH perform
approximately equally well in identifying BRCA1 mutation
carriers. Interestingly, one of the misclassified BRCA1
mutated cases was positive for ER staining. About 5% of
BRCA1-mutated tumours are ER+ [27]. We observed
before (data not published) that ER+ mutation carriers
show a different pattern of copy number changes than tri-
ple-negative mutation carriers. Also, the literature suggests
that ER+ tumours in mutation carriers is a different entity
of disease, as these tumours usually arise later in life and
are less aggressive than the TN tumours [27].
Based on aCGH data, both a BRCA1- and a BRCA2-
like genomic profile can be obtained [6,8]. A limitation
of MLPA compared to aCGH is that information on a
restricted number of genomic loci is obtained. A
BRCA2-like profile cannot yet be obtained by MLPA for
these tumours and 5 to 10% of triple-negative tumours
show such a BRCA2-like profile and these may have the
same hypersensitivity to intensive alkylating therapy
(unpublished data). The translation of the BRCA2-pro-
file to a MLPA kit will be a challenge, as it makes use of
771 probes, rather than the 191 probes of the BRCA1
classifier. MLPA is limited to a maximum of 50 probes,
including reference probes, and ideally each important
genomic region is covered by a minimum of two probes.
For our clinical workup we now use the following rou-
tine for triple-negative tumours. First, a MLPA for
BRCA1-like pattern is performed. If the tumour shows a
BRCA1-like
MLPA pattern, in the clinical diagnostics set-
ting, we can continue with extra analysis sorting out the
defect (that is, methylation analysis). In the therapy
selection setting, the patient can be eligible for protocol
treatment in an intensified alkylating chemotherapy
study (for example, trial NCT01057069 [28]). This study
also serves as a prospective validation of our MLPA
assay. If the tumour shows a Sporadic-like profile, there
is still the possibility that the tumour would be BRCA2-
like at aCGH. Therefore, for these patients aCGH analy-
sis could still be useful.
Conclusions
In conclusion, we have shown that the BRCA1-like
MLPA assay can be both applied in clinical genetic test-
ing and in treatment benefit prediction. As the MLPA
assay is rapid and robust, can easily be multiplexed, and
works well with DNA derived from paraffin-embedded
tissues, it is a suitable method for a clinical application.
However, both its use in the clinical genetics as in the
treatment prediction setting should be validated in large
prospective series.
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